- Boeing and SpaceX Aren't Going Anywhere Without Biotechnology
It isn't rocket science. No, really, it isn't. Big powerful rockets may get us to Mars, but our trips to the Red Planet won't succeed without biological tools.
- Alnylam's RNAi Failure Could Catch Monsanto Investors Off Guard
Investors often associate biotech with healthcare, but biological technologies are applied across unrelated industries. This biopharma failure could have consequences for next-generation agricultural products at Monsanto and Intrexon.
- Don't Believe Elon Musk on the Powerwall
Moving to an application-specific chemistry improved the Powerwall, but the company's marketing clashes with thermodynamics -- and thermodynamics wins every time.
- Myriad Genetics Shouldn't Overlook This Tiny Competitor
Invitae is shaking up how the genetic testing industry operates -- and that has already caused trouble for Myriad Genetics.
- Here's Why Food Security May Be One of the Best Investments of the 21st Century
As the global population increases, the amount of quality arable land is decreasing. New technologies will be key to avoiding future food crises.
- This Farming Tool Is Failing. Can Intrexon Bail Out an Industry?
Agricultural technology companies have had few answers to insects resistant to Bacillus thuringiensis, which threatens a sharp increase in insecticide use without effective solutions.
- Does This Intrexon Opportunity Dwarf Zika Virus?
The company's tool for controlling the spread of Zika virus and other mosquito-borne illnesses may get all of the press, but it may not be the most financially important product for investors.
- Intrexon and Zika Virus: An Interview With Oxitec's Hadyn Parry
A new tool for combating mosquito-borne illnesses targets the source with unparalleled accuracy. Oxitec CEO Hadyn Parry talks about pioneering self-limiting mosquitoes.
- The $100 Million Platform Intrexon Investors Forgot
Investors seem fixated on the company's Zika virus tools and healthcare pipeline, but there's a sweet opportunity with near-term revenue potential going unnoticed.
- Why Intrexon Won't Commercialize Fuels by 2018
The company may be promising to have commercial sales of fuels by 2018 or shortly thereafter, but investors should adjust their expectations.